Desai, Jayesh http://orcid.org/0000-0003-4246-9344
Fong, Peter
Moreno, Victor http://orcid.org/0000-0001-6099-4236
Frentzas, Sophia
Meniawy, Tarek
Markman, Ben
Voskoboynik, Mark
Rahman, Tahmina
Budha, Nageshwar
Wu, John
Marlow, Jin
Yang, Silu
Calvo, Emiliano
Martin-Liberal, Juan
Funding for this research was provided by:
BeiGene, Ltd.
Article History
Received: 4 May 2022
Revised: 8 December 2022
Accepted: 15 December 2022
First Online: 16 February 2023
Competing interests
: JD has received consulting or advisory fees from Amgen, Bayer, BeiGene, Eisai, and Pierre Fabre; research grants from AstraZeneca/Medimmune, BeiGene, Bionomics, Bristol-Myers Squibb, GlaxoSmithKline, Lilly, Novartis and Roche. PF has received honoraria for advisory board for MSD and travel grant from Pfizer. VM has received consulting fees from Roche, Bayer, BMS, Janssen and Basilea. SF received financial/honoraria from Akesobio, Amgen, and MSD and has non-financial relationships with Akesobio, Ambrax, Amgen, AstraZeneca, Beigene, Daiichi Sanjyo, Takeda, HaiHe Biopharma, Aulos, Edison Oncology, MSD, ISOFOL, Vivace and WMS. TM has received advisory fees from Bristol-Myers Squibb, MSD and AstraZeneca. BM has received advisory fees from Amgen, Bristol-Myers Squibb, Merck and BeiGene. MV has received honoraria from MSD; and advisory fees from AstraZeneca. TR is an employee of BeiGene and has no competing interests. NB is an employee of BeiGene and has no competing interests. JW is an employee of BeiGene and has no competing interests. JM is an employee of BeiGene and has no competing interests. SY is an employee of BeiGene and has no competing interests. EC has been a consultant or had an advisory role at Adcendo, Alkermes, Amcure, Amunix, Anaveon, AstraZeneca/MedImmune, BeiGene, Boehringer Ingelheim, Bristol-Myers Squibb, Chugai Pharma, Janssen-Cilag, MonTa, MedSIR, MSD Oncology, Nanobiotix, Nouscom, Novartis, OncoDNA, Roche/Genentech, PharmaMar, PsiOxus Therapeutics, Sanofi, Seattle Genetics, Servier, Syneos Health, TargImmune, T-Knife and research grants from Achilles, BeiGene, START. JM-L has received lecture fees from Astellas, Bristol-Myers Squibb, MSD, Novartis, Pierre Fabre, Pfizer, Roche and Sanofi; advisory fees from Bristol-Myers Squibb, Highlight Therapeutics, Novartis, Pierre Fabre, Roche and Sanofi; research grants from Sanofi; and travel grants from Bristol-Myers Squibb, MSD, Novartis, Pierre Fabre, Pfizer, Roche and Ipsen.
: This study was conducted in accordance with Good Clinical Practice and all applicable regulatory requirements, including, where applicable, the current version of the Declaration of Helsinki. The protocol was approved by the following ethics committees: CEIm Hospital Universitario y Politécnico la Fe Avenida Fernando Abril Martorell; Bellberry Limited Human Research Ethics Committee; Melbourne Health Human Research Ethics Committee; Health and Disability Ethics Committee, and was monitored by a safety monitoring committee. Informed consent was obtained before patients participated in the study. The contents and process of obtaining informed consent(s) was in accordance with all applicable regulatory requirements.
: Not applicable.